Small Doses: Pharmacy News Featuring Opioids, Ketamine, and More Small Doses is news for pharmacists in a way that works for you. New Products: Neuromodulation system for OAB targets tibial nerve July 15, 2016 By Ben Schwartz Other products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more. Brain activity in OAB patients characterized in study Preliminary findings of a Swiss study revealed that the brain activity associated with the desire to void in response to the automated, repetitive filling and distention of the bladder with body warm saline differed greatly between healthy patients and patients with non-neurogenic overactive bladder. Botulinum formulations show slight outcomes differences A new comparative study showed that the use of intradetrusor injections of abobotulinum toxin A (Dysport) for urinary incontinence due to neurogenic detrusor overactivity provided results that were similar to or superior to those seen with onabotulinum toxin A (Botox), depending on the dosage of the latter. Treatment of OAB may reduce fall risk in older patients February 29, 2016 By Annamarie Iannetta Overactive bladder (OAB) and falls often carry a substantial burden for patients and society as a whole, and new research suggests that treatment of OAB may lower fall risk. Learn more PTNS efficacy bolstered by adjunctive pharmacotherapy December 07, 2015 By Louise Gagnon Study examines real-world effectiveness of percutaneous tibial nerve stimulation for treating overactive bladder. CNS may be path to future voiding dysfunction therapies In this interview, Karl-Erik Andersson, MD, PhD, discusses current treatments for common voiding dysfunctions and future directions, including central nervous system agents and combination therapies. Uro Pipeline: Phase III data show drug’s benefit in castrate-resistant PCa December 01, 2015 By Benjamin P. Saylor Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder. Uro Pipeline: IDE approval granted for implantable neurostimulator November 01, 2015 By Benjamin P. Saylor A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up. Neuromodulation adverse events characterized October 26, 2015 By Louise Gagnon Researchers recently presented 12-month follow-up data from a prospective, multicenter trial of a device for sacral neuromodulation.